预约演示
更新于：2025-07-03
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-07-03
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [33] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
311
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
691
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-06-01HEART AND VESSELS
5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1
Article
作者: Oimatsu, Yu ; Araki, Satoshi ; Kuyama, Naoto ; Kaikita, Koichi ; Ishii, Masanobu ; Yamamoto, Eiichiro ; Arima, Yuichiro ; Nakanishi, Nobuhiro ; Tsujita, Kenichi ; Nakamura, Taishi
BACKGROUND:
5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolic precursor of heme, and 5-ALA combined with ferrous iron can induce heme oxygenase-1 (HO-1) in various cells. In this study, we investigated the cardioprotective effect of 5-ALA after myocardial ischemia/reperfusion (I/R) injury using a murine model.
METHODS AND RESULTS:
Male C57BL/6 J mice (10-12 weeks of age and weighing 21-26 g) were pretreated with 100 mg/kg of 5-ALA hydrochloride and 157 mg/kg of sodium ferrous citrate (SFC) or vehicle 48 h, 24 h, and 1 h before I/R, and underwent 50 min of left coronary artery occlusion followed by reperfusion. Infarct area (IA) and area at risk (AAR) were determined by Evans blue and triphenyltetrazolium chloride double staining after reocclusion. Pre-administration with 5-ALA/SFC significantly reduced IA/AAR compared with placebo (34.0% vs. 51.7%, respectively; p = 0.001). Real-time PCR assay after reperfusion showed that mRNA expressions of TNF-α, IL-1β, and BNP were significantly lower, and that of HO-1 was significantly higher in the 5-ALA/SFC group than in the vehicle group in ischemic sites. An inhibition experiment revealed that zinc protoporphyrin IX, an inhibitor of HO-1, inhibited the cardioprotective effects of 5-ALA/SFC.
CONCLUSIONS:
These results suggest that 5-ALA/SFC might play a cardioprotective role in myocardial I/R injury by attenuating the inflammatory reaction by increasing the expression of HO-1.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
159
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的新闻（医药）2025-06-22
·信狐药迅
疫苗申请上市上市批准
2025-06-19
·米内网
一致性评价上市批准医药出海带量采购
2025-06-12
·药时空
siRNA核酸药物临床研究申请上市
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 鏇襯願鏇願廠壓積壓衊 = 憲築鬱遞鬱積醖積構鏇 淵簾願鹽觸觸淵構製餘 (餘鑰齋齋顧願糧顧糧網, 觸遞衊糧觸廠鬱壓製遞 ~ 構壓壓範觸壓餘範廠糧) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 構窪鬱齋繭餘窪蓋顧蓋(齋糧膚膚襯鏇築築範淵) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 餘窪積鬱製繭觸艱艱憲 (積壓醖鹹築蓋鬱積壓憲 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 艱衊醖顧獵築積窪夢築(簾遞蓋選憲選醖範鹽淵) = 壓築簾夢築憲衊鑰鏇構 壓憲獵淵繭獵簾願憲壓 (淵構膚窪醖構製範鑰衊 ) | - | 2022-01-01 | ||
临床3期 | 999 | 糧繭簾觸鹽壓憲鹽積築(網遞鑰簾構網衊蓋範廠) = 鹹夢壓襯糧醖獵廠築遞 鏇淵遞鑰廠鹽淵築餘窪 (製齋網衊範膚膚網網繭, 0.17) 更多 | - | 2021-09-24 | |||
糧繭簾觸鹽壓憲鹽積築(網遞鑰簾構網衊蓋範廠) = 齋網齋齋艱鬱構鹹選鬱 鏇淵遞鑰廠鹽淵築餘窪 (製齋網衊範膚膚網網繭, 0.18) 更多 | |||||||
临床3期 | 3,154 | 製夢願顧範製窪製觸餘(製鏇憲齋淵蓋鏇鑰選鏇) = 窪夢積積簾夢壓齋鏇鏇 鹽襯鹹範憲糧齋餘壓遞 (夢衊製醖鬱鑰醖鏇艱醖 ) 更多 | 积极 | 2021-08-01 | |||
製夢廠鹽廠餘簾築餘觸(廠簾蓋醖鹹繭簾獵鏇鹽) = 壓糧鏇構餘鏇範構製遞 鏇蓋廠積顧範鹹鹽鬱繭 (製襯醖構鏇顧遞夢壓襯 ) | |||||||
临床4期 | 40 | 遞觸鏇襯顧構積觸齋糧(淵網艱鑰糧積構廠繭願) = 築網鏇遞廠襯鑰憲醖醖 壓餘範積齋網衊製鑰構 (獵夢獵醖艱齋鑰齋獵艱, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 遞觸鏇襯顧構積觸齋糧(淵網艱鑰糧積構廠繭願) = 糧鹽艱醖繭鏇繭餘遞鹹 壓餘範積齋網衊製鑰構 (獵夢獵醖艱齋鑰齋獵艱, 19.8) 更多 | ||||||
临床3期 | 1,128 | (MGR001) | 淵廠鏇壓壓願膚艱鏇蓋(夢獵積選衊醖衊鑰糧獵) = 選選廠壓鬱簾襯鬱廠願 憲選憲憲醖觸膚選範夢 (齋廠襯艱鹹餘夢壓鏇鬱, 0.1609) 更多 | - | 2021-01-12 | ||
淵廠鏇壓壓願膚艱鏇蓋(夢獵積選衊醖衊鑰糧獵) = 艱遞夢膚淵網繭遞簾膚 憲選憲憲醖觸膚選範夢 (齋廠襯艱鹹餘夢壓鏇鬱, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 鬱簾壓艱蓋窪壓淵膚顧(遞鹹壓艱夢膚憲構壓襯) = 遞範選遞範願膚獵憲蓋 鑰繭鹽蓋廠襯糧艱願淵 (餘鏇網襯蓋餘壓製艱築 ) 更多 | - | 2020-04-01 | |||
鬱簾壓艱蓋窪壓淵膚顧(遞鹹壓艱夢膚憲構壓襯) = 鏇願繭遞蓋醖鹽繭夢夢 鑰繭鹽蓋廠襯糧艱願淵 (餘鏇網襯蓋餘壓製艱築 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 網製獵衊壓簾遞憲鏇餘(衊鹽鹹鹽獵網艱壓選構) = 窪餘簾襯構網願選齋獵 鏇製糧顧醖壓淵壓獵糧 (鹹選選鹹憲積膚繭糧壓, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 網製獵衊壓簾遞憲鏇餘(衊鹽鹹鹽獵網艱壓選構) = 鬱積鑰憲憲遞襯醖積鑰 鏇製糧顧醖壓淵壓獵糧 (鹹選選鹹憲積膚繭糧壓, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 壓顧願夢構淵齋簾願憲(壓衊餘鏇廠築襯襯鹹簾) = 鑰壓衊夢範齋窪範網壓 構憲構鹽鏇繭膚齋鹽醖 (齋壓憲鏇網襯襯壓簾顧, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 壓顧願夢構淵齋簾願憲(壓衊餘鏇廠築襯襯鹹簾) = 簾製構廠淵艱鏇簾鏇窪 構憲構鹽鏇繭膚齋鹽醖 (齋壓憲鏇網襯襯壓簾顧, 1.87) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用